Loading
A phase 2 trial of IO102-IO103 in melanoma, run by IO Biotech, now recruiting.
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors is a phase 2 interventional study registered as NCT05280314 by IO Biotech, with 60 participants planned, started 2023-12-21 and due to reach its primary completion in 2025-04-30. Interventions recorded: IO102-IO103, Pembrolizumab KEYTRUDA®. Conditions listed: Melanoma, Squamous Cell Carcinoma of Head and Neck. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IO Biotech, IO102-IO103, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/